Crossmark

Phase II Trial of S-1 and Oxaliplatin Plus Cetuximab for Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases (KSCC1002)

Crossref DOI link: https://doi.org/10.1245/s10434-015-4771-1

Published Online: 2015-09-03

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oki, Eiji

,

Emi, Yasunori

Miyamoto, Yuji

Kabashima, Akira

Higashi, Hidefumi

Ogata, Yutaka

Ikebe, Masahiko

Saeki, Hiroshi

Tokunaga, Shoji

Shirabe, Ken

Beppu, Toru

Uchida, Shinji

Takatsuki, Mitsuhisa

Sakoda, Masahiko

Eguchi, Susumu

Akagi, Yoshito

Kakeji, Yoshihiro

Baba, Hideo

Natsugoe, Shoji

Maehara, Yoshihiko
License Information

Text and Data Mining valid from 2015-09-03

Updates are available Correction dated 2015-09-21

Click to view Correction: https://doi.org/10.1245/s10434-015-4864-x